The four members of the ErbB family of receptor tyrosine kinases are involved in development and tumorigenesis of the mammary gland. Whereas the epidermal growth factor receptor, ErbB2 and ErbB3 are positively associated with various cancers, clinical studies of ErbB4 in breast cancer are contradictory. Results from tissue culture analyses and some clinical studies suggested that ErbB4 is either a tumor suppressor or is a negative regulator of ErbB2-driven tumors. Neu-Cre-ErbB4 flox/null mice in which ErbB4 was inactivated by Cre-lox-mediated recombination in the mammary gland developed MMTVNeu-driven mammary tumors with a similar latency period to mice with one or two wild-type ErbB4 alleles. Moreover, there was no difference in the histologies of tumors that developed, nor in the propensity to form lung metastases. Taken together these results suggest that ErbB4 is not a potent, highly penetrant tumor suppressor, nor is it a factor in Neu-mediated tumorigenesis in this model.
Introduction
Receptor tyrosine kinases (RTKs) in the epidermal growth factor receptor (EGFR) family are important human oncogenes and therapeutic targets. Amplification, overexpression and/or mutation of the EGF receptor is common in glioblastoma, non-small cell lung carcinoma and colorectal carcinoma and mutations in this receptor in non-small cell lung carcinoma may be associated with responsiveness to the EGFRtargeted drug Iressa (Gefitinib) (von Mehren, 2005) . The second member of the family, ErbB2/HER2/Neu, is overexpressed, owing to gene amplification, in approximately one-fourth of mammary and ovarian carcinomas, and overexpressed without amplification in several other carcinomas (Stern, 2000) . Mutations in the kinase domain have been found with low prevalence in the adenocarcinoma subtype of non-small cell lung carcinoma (Stephens et al., 2004) . HER2 is the target for the therapeutic antibody Herceptin (Trastuzumab), which has been approved by the United States Federal Drug Administration for treatment of advanced breast cancer with high expression of ErbB2. The third member of the EGFR family is ErbB3, an unusual receptor kinase with little or no intrinsic catalytic activity. ErbB3 is often overexpressed in mammary carcinoma, which in some cases may occur through collaboration with ErbB2 (Siegel et al., 1999) . Cooperation of ErbB2 and ErbB3 is important for aggressiveness of ErbB2-overexpressing cancers (Olayioye et al., 2000) .
The fourth member of the EGFR family is ErbB4. In contrast to studies on overexpression and/or activation of EGFR, ErbB2 and ErbB3, research studies comparing ErbB4 overexpression to outcome of carcinomas are sparse and somewhat contradictory (Gullick, 2003) . ErbB4 overexpression is associated with poor prognosis for thyroid cancer and childhood medulloblastoma (Haugen et al., 1996; Gilbertson et al., 1997) . Somatic mutations in the ErbB4 kinase domain were detected at a low frequency in gastric carcinomas, colorectal carcinomas, non-small lung cancers and breast carcinomas (Soung et al., 2006) . One early survey revealed that ErbB4 expression is lower in breast and prostate cancer specimens than in normal tissue, and, in contrast to ErbB2, tended to be associated with differentiating tissue, rather than proliferating tissue (Srinivasan et al., 1998) . However, later work from the same laboratory identified a low (7%) frequency of mammary carcinomas with ErbB4 overexpression in addition to carcinomas with lower expression of ErbB4 in comparison to adjacent normal tissue (18%) . Clinical outcome studies showed that ErbB4 overexpression in breast cancer is positively associated with estrogen receptor (ER) and/or progesterone receptor (PR), which themselves are associated with better prognosis, whereas ErbB2 overexpression was associated inversely with PR (Bacus et al., 1996; Knowlden et al., 1998; Tang et al., 1999) . Similarly, a study of mammary carcinoma (N ¼ 127) linked ErbB4 with differentiated histology and other features associated with better prognosis (Kew et al., 2000) . In a comparison of mRNAs for all four ErbBs, ErbB3 and ErbB4 mRNAs were positively associated with ER and PR, and negatively with histological grade, whereas mRNA for EGFR and ErbB2 were associated inversely with ER and PR, and positively with grade (Pawlowski et al., 2000) .
A large number of clinical studies have linked ErbB2 amplification and/or overexpression with poor prognosis in breast cancer (Olayioye et al., 2000) . Collaborative work including our laboratory revealed that high ErbB2 signaling activity is associated with poor outcome in breast cancer, and that this activity (and negative prognosis) is itself associated with high expression of the EGFR (Thor et al., 2002; DiGiovanna et al., 2005) . Several studies have now compared ErbB4 expression with clinical outcome. In an analysis of 220 primary breast cancer biopsies associated with up to 16 years clinical follow-up, overexpression of EGFR, ErbB2 and ErbB3 were associated with ER-negative and poorer prognosis. However, ErbB4 overexpression was associated with ER-positive (weak), lower grade, and significantly better outcome (Witton et al., 2003) . In approximately 100 mammary carcinomas, mRNA and protein for ErbB4 was positively correlated with ER expression (Suo et al., 2001) . Significantly, ErbB4 expression was associated with favorable outcome in a study of 100 mammary carcinoma patients, in contrast to ErbB2 (Suo et al., 2002) . In a study of 129 cases of ductal carcinoma in situ, the absence of ErbB4 predicted recurrence within a 5-year-period, and co-expression of ErbB2 and ErbB4 resulted in a lower risk of recurrence that expression of ErbB2 alone (Barnes et al., 2005) . Taken together, these results support a possible association of ErbB4 overexpression with favorable outcome in mammary carcinoma, and underexpression with a more aggressive tumor phenotype.
However, the clinical literature is not entirely consistent in supporting this conclusion (reviewed in Gullick (2003) ). In a panel of primary breast tumors from 130 women, a high-ErbB4 mRNA level was associated with shorter relapse-free survival (RFS), whereas neither EGFR nor, surprisingly, ErbB2, were associated with RFS (Bieche et al., 2003) . In a study of 66 patients, high cytoplasmic expression of ErbB4 was associated with reduced overall survival (Lodge et al., 2003) .
The consequences of ErbB4 activation may depend upon the presence and activity of other receptors in the system under analysis. Suo et al. (2002) reported that ErbB4 expression mitigates the association of ErbB2 with negative clinical course of breast carcinomas, and ErbB4 expression was associated with a more favorable outcome (Suo et al., 2002) . However, Lodge et al. (2003) also compared all four ErbBs and found that patients with high ErbB4 fared significantly worse than those with low expression (Lodge et al., 2003) . Abd El-Rehim et al. (2004) found no association between ErbB4 and survival, whereas EGFR and ErbB2 were negatively associated with survival (Abd El-Rehim et al., 2004) .
The hypothesis that ErbB4 is a negative regulator of tumor growth is consistent with tissue culture data linking ErbB4 to differentiation and apoptosis, as well as proliferation. ErbB4 and ErbB3 are receptors for Neuregulins (NRGs), which induce differentiation of some mammary carcinoma cell lines (Bacus et al., 1996) . Agonistic ErbB4 cross-linking antibodies cause cells to differentiate (Chen et al., 1996) , and constitutively active alleles of ErbB4 do not malignantly transform the growth of fibroblast or prostate cancer cell lines (Penington et al., 2002; Williams et al., 2003) . Expression of ErbB4 in SUM-102 breast cancer cells enabled a differentiative response to the agonist NRG, and dominant-negative inhibition of endogenous ErbB4 in SUM44 cells reduced NRG-dependent growth inhibition (Sartor et al., 2001) . However, ErbB4 has a role in stimulating growth as well. Ribozyme-mediated downregulation of ErbB4 mRNA suppressed growth of mammary carcinoma cell lines (Tang et al., 1998 (Tang et al., , 1999 , and NRG induced focus formation by NIH3T3 cells expressing ErbB4 (Cohen et al., 1996) .
The general pattern that ErbB4 is associated with differentiation and/or morphogenesis, rather than simply proliferation, is supported by mammary organ and tissue culture studies (Yang et al., 1995) . Similarly, in mouse mammary gland development, ErbB4 signaling is important for final stages of differentiation and maintenance of lactation, but is not required for proliferation of mammary epithelial cells during puberty or in pregnancy (Jones et al., 1999; Long et al., 2003; Tidcombe et al., 2003) .
In summary, a number of in vivo and tissue culture observations indicate that EGFR and ErbB2 are human oncogenes and positive regulators of cell growth. ErbB4 activities are different, since this receptor is more tightly linked to differentiation and, in some contexts, apoptosis. Hence, in contrast to EGFR and ErbB2, which are human oncogenes, we have hypothesized that ErbB4 is negatively associated with carcinogenesis, at least in mammary carcinoma (Stern, 2000 We have tested two hypotheses. The first is that ErbB4 is an autonomously acting tumor suppressor. This was investigated by determining the rate of spontaneous tumor formation in mice that are unable to express ErbB4 in most tissues. The second hypothesis is that ErbB4 impedes the pro-carcinogenic activities of other ErbBs. Hence, we determined whether elimination of ErbB4, through recombination of a floxed ErbB4 allele, affects the rate and/or penetrance of tumors induced by enhanced mammary-specific expression of the proto-oncogene ErbB2.
Results
To determine if ErbB4 is a tumor suppressor gene in mice, we first evaluated the age-dependent formation of tumors in ErbB4 À/À mice. ErbB4 is essential for cardiac development. The embryonic lethality associated with constitutional disruption of ErbB4 can be bypassed by expression of a human HER4 cDNA in the heart under control of a mouse a-myosin heavy chain promoter (Tidcombe et al., 2003) . ErbB4 À/À animals carrying this HER4 heart transgene reach adulthood and are fertile, but have cranial nerve and cerebellar defects, and impaired mammary differentiation and lactation. Four HER4 heart ErbB4 þ / þ mice, 19 HER4 heart ErbB4 þ /À mice, and 13 HER4 heart ErbB4 À/À mice were aged for 1-2 years and monitored for development of mammary gland tumors. Over this period, two ErbB4 þ /À mice and one ErbB4 À/À mouse developed mammary tumors. Thirteen of the aged HER4 heart mice, including the three that developed mammary tumors, three additional ErbB4
þ /À mice, and two ErbB4 þ / þ mice, were necropsied, and did not show gross signs of tumorigenesis in any other tissue. Hence, ErbB4 is not a highly penetrant tumor suppressor gene.
A second hypothesis was that ErbB4 negatively modulates tumors induced by other means, including activation of other ErbBs. For this purpose, we used a system in which tumors are induced by the MMTV-Neu transgene, which causes mammary-specific expression of a wild-type rat ErbB2 cDNA. This transgene promotes efficient formation of tumors with a lengthy latency period of approximately 205 days (Guy et al., 1992) . In contrast, mice that express a mutant form of Neu that is constitutively active due to an amino-acid substitution in the transmembrane domain, develop tumors with a short latency period of 89 days (Muller et al., 1988) . The longer latency period of tumors induced by wild-type MMTV-Neu is caused by the requirement for additional genetic events to enable tumor formation. These tumors generally harbor somatic mutations that constitutively activate ErbB2 by promoting inter-receptor disulfide bond formation (Siegel et al., 1994) . Tumorigenesis induced by MMTV-Neu can also be accelerated through cooperation with other genetic lesions, including overexpression of TGF-a or a dominant active form of p53 (Muller et al., 1996; Li et al., 1997) . Hence, we anticipated that this system would be highly sensitive to any biological changes associated with loss of ErbB4 that would either accelerate or decelerate tumorigenesis.
To determine if ErbB4 has an antagonistic effect on MMTV-Neu-driven tumorigenesis, we employed the Cre-lox recombinase system to generate mice that would lack ErbB4 in the mammary epithelium. We used a 'floxed' ErbB4 mouse with loxP sites in introns 1 and 2 of the ErbB4 locus (Long et al., 2003) . Mice homozygous for the loxP-flanked ErbB4 allele appear normal and are fertile. Cre-mediated recombination of the loxP flanked ErbB4 allele (flox) will excise the second exon, which results in the same loss-of-function mutation as reported for the null allele (Gassmann et al., 1995) . To specifically delete ErbB4 in the mammary epithelium, Cre recombinase expression was driven by the MMTV promoter. The breeding strategy for generation of mice carrying the two transgenes (MMTV-Neu and MMTVCre) and the two modified ErbB4 alleles necessary for ErbB4 ablation in the mammary gland (floxed ErbB4 allele and the ErbB4 null allele) is depicted in Figure 1 . Expression of both wild-type Neu and Cre recombinase genes under control of the MMTV promoter, should increase the likelihood that ErbB4 would be deleted in the same cell types as express the oncogenic MMTV-Neu transgene. Two populations of mice were obtained from the final cross. MMTV-Neu/ þ MMTV-Cre/ þ ErbB4 flox/null mice, hereafter referred to as the Neu-CreErbB4 flox/null mice, will lack ErbB4 in the mammary gland flox/WT mice were produced and monitored for tumor formation under blinded conditions.
In order to maximize expression of the hormonallydriven MMTV promoters driving Neu and Cre, females from both genotypes were kept in constant breeding. Both the Neu-Cre-ErbB4 flox/null and Neu-Cre-ErbB4 flox/WT mice were fertile and able to support litters. Maintenance of animals in pregnancy further enhanced activity of the MMTV-driven transgenes, and favored expression of endogenous ErbB4, which is expressed in adult female mammary epithelium, and is active in signaling during pregnancy and lactation (Schroeder and Lee, 1998; Jones et al., 1999) . Sixty two of the 65 Neu-Cre-ErbB4 flox/WT mice developed mammary tumors. Of these, tumors from 24 (38.7%) of the animals had recombined the floxed ErbB4 allele as assessed by PCR (Figure 2a Recombination of the floxed ErbB4 allele in Neu-CreErbB4 flox/null mice directly correlated with an absence of ErbB4 protein in mammary gland tissue and tumors (Figure 2b ). Full length ErbB4 protein was immunoprecipitated from mammary glands protein lysates of three pregnant or lactating recombined Neu-CreErbB4 flox/WT mice (Figure 2b, lanes 1-3) , and from mammary tumors from two of the same mice (lanes 9 and 10). We do not know if the failure to detect ErbB4 in lane 2 reflects lack of ErbB4 expression in this sample, or is an artifact arising from protein degradation or other technical issues. Including other data not shown, ErbB4 protein in recombined Neu-Cre-ErbB4 flox/WT mice was evident in two out of the three mammary glands and all seven tumors analysed. ErbB4 protein expression was not detected in mammary gland protein extracts from three pregnant or lactating recombined Neu-CreErbB4 flox/null mice ( Figure 2b , lanes 4-6), nor in mammary tumors from the same three mice (lanes 12-14) , or in any of seven other recombined Neu-Cre-ErbB4 flox/null tumor samples analysed (lane 11 and data not shown). As MMTV-Cre should only be expressed in the epithelium, low level expression of ErbB4 protein may occur in stromal cells in recombined Neu-Cre-ErbB4 flox/null mice (lanes 4-6).
Membrane-anchored and soluble intracellular forms of ErbB4 are generated by proteolytic cleavage (Elenius et al., 1997) . In some ErbB4 immune complex samples, we did detect bands that react specifically with an antibody that recognizes the ErbB4 cytoplasmic domain and that migrates in the appropriate size range for the cleavage products, approximately 70-80 kDa (e.g., Figure 2b , lanes 9 and 10, and Figure 2c , lane 3). However, it is not clear whether these are specific 1-7) or mammary tumor protein lysates (lanes 9-15) prepared from recombined Neu-Cre-ErbB4 flox/WT mice (lanes 1-3, and 9-10), from recombined NeuCre-ErbB4 flox/null mice (lanes 4-6, and 11-14), and from a non-recombined Neu-ErbB4 flox/flox mouse (P, lanes 7 and 15). The numbers above the lanes refer to specific mice. For a marker, human ErbB4 was immunoprecipitated from protein lysates from COS-7 cells transfected with a plasmid encoding full length human ErbB4. The ErbB4 immunoprecipitates were probed with anti-ErbB4 antibody. The relative protein levels were determined by probing 100 mg of total protein extract with an antibody specific for b-tubulin. To determine if the presence or absence of ErbB4 in the mammary gland affected the latency period for MMTV-Neu tumorigenesis, we compared the rate of tumor formation in each of the four groups of mice generated (Figure 3) . The median age of tumor onset was slightly earlier than the originally reported 205 days (Guy et al., 1992) , yet significantly beyond the 89 days reported for tumors induced with activated Neu (Muller et al., 1988 flox/WT , P ¼ 0.031), nuclear atypia (8/10 tumors versus 5/10 tumors), and were of higher nuclear grade (average of 1.8 versus 1.4). The mice had between zero and three additional tumors in the mammary glands, but tumors were not found by gross analysis in any other tissue.
We next evaluated frequencies of pulmonary metastasis in recombined Neu-Cre-ErbB4 flox/WT , recombined Neu-Cre-ErbB4 flox/null , and non-recombined Neu-CreErbB4 flox/WT mice. Pulmonary metastases were scored by histological examination of two sections per lung. In this sample, 35% (8 out of 23) of the recombined NeuCre-ErbB4 flox/WT , 25% (9 out of 36) of the recombined Neu-Cre-ErbB4 flox/null , and 19% (7 out of 37) nonrecombined Neu-Cre-ErbB4 flox/WT mice had lung metastases. The difference observed was insignificant (P ¼ 0.3860). Of the mice that had lung metastases, the median number of metastases detected was two for both the recombined Neu-Cre-ErbB4 flox/WT mice and the nonrecombined Neu-Cre-ErbB4 flox/WT mice. The median number of lung metastases was five for the recombined Neu-Cre-ErbB4 flox/null mice. Overall, we conclude that the presence or absence of ErbB4 does not significantly alter either the latency period of tumors induced by MMTV-Neu, or their propensity to form lung metastases.
Discussion
The EGFR gene ERBB, and ERBB2 are bona fide human oncogenes that, when activated by gene alterations, promote cell proliferation, and formation of aggressive cancers. This has made both of these receptors attractive therapeutic targets, and the US Federal Drug Administration has approved drugs that target each of these receptors. These drugs appear to be ). Log-rank P ¼ 0.1152.
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effective for a subset of tumors involving these oncogenes. Iressa/Gefitinib is most effective in a subset of non-small cell lung carcinomas in which the receptors are mutated (Lynch et al., 2004; Paez et al., 2004) . These mutations cause receptor activation, and concomitantly sensitize cells to Iressa. Herceptin/Trastuzumab is most effective for breast cancers that express ErbB2 at high levels, which itself may signify high ErbB2 activity from homodimerization or heteromerization with other ErbBs (Vogel et al., 2002) . In order to best exploit these drugs, it will be important to distinguish the biological activities associated with the receptors, including, potentially, modulation by ErbB3 and ErbB4 (Stern, 2000) . In contrast to the EGFR and ErbB2, studies on the role of ErbB4 in cancer have been contradictory. Convergent evidence from tissue culture studies, work in animal models, and analysis of human tumor biopsies, led ourselves and others to hypothesize that endogenous ErbB4 negatively modulates mammary carcinogenesis, either through its ability to form heteromers with and bind ligands for other members of the EGFR family, or as an autonomous tumor antagonist or tumor suppressor. The data reported here do not support the hypothesis that ErbB4 is a potent, highly penetrant, tumor suppressor. In the mammary gland, there was no evidence for precocious tumor formation resulting from recombination of Neu-Cre-ErbB4 flox/null (leading to a null genotype after recombination) relative to either recombined Neu-Cre-ErbB4 flox/WT (hemizygous genotype after recombination) or non-recombined Neu-CreErbB4 flox/WT (homozygous þ / þ ). Similarly, aging of HER4 heart ErbB4 À/À animals, in which ErbB4 expression is largely confined to the heart, did not yield an exceptional number of gross tumors in any tissue. The second hypothesis that we tested was that ErbB4 might modulate (negatively or positively) the rate of tumor formation induced by MMTV-Neu. However, we found that mammary tumors induced by MMTV-Neu developed with the approximately the same incidence and time course in ErbB4 homozygotes (non-recombined Neu-Cre-ErbB4 flox/WT ), heterozygotes (recombined NeuCre-ErbB4 flox/WT ; non-recombined Neu-Cre-ErbB4 flox/null ) and nulls (recombined Neu-Cre-ErbB4 flox/null ). Tumor histology was similar among the recombined Neu-CreErbB4 genotypes as was the propensity to form lung metastases.
Although the focus of the present manuscript was on loss of ErbB4 function in tumorigenesis, most of the clinical studies on ErbB4 evaluate clinical outcomes associated with ErbB4 overexpression. As discussed in the Introduction, there are a number of inconsistencies among the handful of studies investigating ErbB4 expression in breast cancer in association with prognostic factors and patient outcome data (reviewed in Gullick (2003) ). A number of factors may contribute to these discordances. The methods used to derive the conclusions differ widely. Some groups analysed RNA samples, others tissue samples or protein samples. Variation in handling of samples could cause degradation of the receptor or variation in the results. Also, studies based on immunohistochemistry did not always use the same ErbB4 antibodies. Despite efforts at validation, it is possible that some staining patterns are misinterpreted or that some of the immunostaining was non-specific. 
Most of the studies do not take into account the polymorphism of ErbB4, which is produced in four major isoforms owing to splice choices between exons 14 and 17 and between exons 25 and 27. The former splicing choice results in two different forms of the extracellular juxtamembrane domain, JM-a and JM-b (Elenius et al., 1997) . JM-a, but not JM-b, is subject to cleavage by a TACE-like metalloproteinase followed by an intramembrane cleavage by one or more g-secretases in response to NRGs and protein kinase C agonists (Rio et al., 2000) . This is significant since the free cytosolic cleavage product, which contains the entire intracellular domain, translocates to the nucleus, where it may exercise biological effects through its kinase domain, through binding to YAP, or through transcriptional transactivation activities (Komuro et al., 2003) . Furthermore, a recent study implicates the cleaved ErbB4 as a carrier that chaperones Stat5 to the nucleus (Williams et al., 2004) . A second pair of alternative splices results in Cyt-1 and Cyt-2 isoforms, with the former able to recruit phosphatidyl-inositol 3 0 kinases, which support cell survival through activation of AKT pathways (Elenius et al., 1999) . Overexpression of the JM-a CYT-2 ErbB4 isoform promotes ErbB4 phosphorylation and proliferation of breast cancer cells in the absence of ligand stimulation, and this isoform, in addition to the JM-a CYT-1 isoform, was overexpressed in a subset of breast cancers (Maatta et al., 2006) . Hence, it is possible that differences in biological activities of different ErbB4 isoforms mask the clinical impact of individual isoforms. Recently, real-time polymerase chain reaction (PCR) was used to quantify the different ErbB4 isoforms in normal bladder tissue, interstitial cystitis, and transitional cell carcinoma of the bladder. An increase in the JM-a juxtamembrane isoform in addition to an increase in ErbB2 was seen in the transitional cell carcinoma of the bladder (Junttila et al., 2003) . The same group used real-time PCR to monitor ErbB4 isoforms in clinical breast cancer samples (N ¼ 62). They found that expression of the proteolytically cleavable ErbB4 JM-a isoform transcript is associated with markers for positive prognosis of ER a expression and differentiated tumors (Junttila et al., 2005) . However, nuclear translocation of the proteolytically cleavable ErbB4 JM-a isoform was associated with a poorer prognosis in woman with nuclear staining of ErbB4 as compared to cell membrane staining of ErbB4 in breast cancer tissue array (n ¼ 458) (Junttila et al., 2005) .
Although our experiments do not support the hypothesis that loss of ErbB4 function accelerates carcinogenesis in our models, they do not address the possibility that ErbB4 gain-of-function, through overexpression, activating mutations or constitutive ligand production, modulates mammary carcinogenesis. Further work using mouse models will be invaluable in determining the consequences of overexpression of specific ErbB4 isoforms, as will a concerted effort to decipher the relative contributions of ligand production, mutation, cross-activation and modulation by other hormonal systems in governing ErbB regulation in human cancer. Ultimately, integrated analysis of these components should yield strong benefits in predicting patient outcomes and in appropriate use of current and future ErbB-targeted therapeutics.
Materials and methods
Transgenic mice 'Floxed' mice with ErbB4 exon 2 flanked by loxP sites (Long et al., 2003) were obtained from Dr KC Kent Lloyd, University of California, Davis. ErbB4 null mice (Gassmann et al., 1995) were obtained from Dr Martin Gassmann. MMTV-Neu mice (Guy et al., 1992) were obtained from Jackson Laboratories (strain name: FVB/N-TgN(MMTVneu) 202Mul/J, Stock number: 002376), and MMTV-Cre mice (Andrechek et al., 2000) 0 were used to generate a 700 bp MMTV-Cre product. Homozygosity of the MMTV-Cre transgene was determined by mating to a FVB mouse and subsequent PCR analysis of offspring from at least two litters.
Tumor kinetics analysis
In a blinded study, MMTV-Neu female mice were kept in constant breeding and were palpated for tumors twice weekly. The study was unblinded once all of the mice reached 300 days of age or developed tumors. The mice were killed when the largest diameter of the tumors reached approximately 1.5 cm. Tumors were excised, measured with digital calipers (Chicago Band Industrial, Inc. Fremont, CA, USA) and bisected. Half of each tumor was snap-frozen in liquid nitrogen and stored at À801C for preparation of extracts. The remaining half of the tumor was fixed overnight in freshly prepared 4% paraformaldehyde, transferred to 70% ethanol, paraffin-embedded and sectioned for histology. A complete necropsy was performed on all mice. The lungs were inflated with 10% neutral buffered formalin. The remaining organs including the inflated lungs were fixed overnight in 10% neutral buffered formalin and stored in 70% ethanol. The lungs were bisected into two major lobes, and then each lung section was bisected lengthwise. The four lung sections were paraffin-embedded and two 5-mm sections were stained with hematoxylin and eosin.
Polymerase chain reaction analysis of recombination Genomic DNA was isolated from mammary tumors using the DNeasy Tissue Kit (Qiagen) according to the manufacturer's instructions. A set of three primers was used in order to amplify diagnostic bands for the ErbB4 alleles (Thuret et al., 2004) . These primers amplified a 547 bp fragment for the loxPflanked (floxed) allele before recombination (non-rec), a 507 bp for the floxed allele after Cre-mediated excision of exon 2 (rec), and a 450 bp for the ErbB4 null allele (null). Primer 23: 5 0 -tat tgt gtt cat cta tca ttg caa ccc ag-3 0 at a final concentration of 0.3 mM. Primer SAUPER2: 5 0 -cat cct ctt gtg tgc ttt tgt tgt ac-3 0 at a final concentration of 1.1 mM. Primer PO81: 5 0 -gat gtg gaa tgt gtg cga ggc c-3 0 at a final concentration of 1.1 mM. Genomic tail DNA was used as a negative control for recombination.
Immunoprecipitation and Western blot analysis Mammary glands and tumors were excised and snap-frozen in liquid nitrogen and stored at À801C. Protein lysates were prepared as described (Schroeder and Lee, 1998) , with the following modifications: the Triton X-100 lysis buffer also contained Complete Protease Inhibitors (Roche Diagnostics, Mannheim, Germany), and Phosphatase Inhibitor Cocktail II (Sigma-Aldrich, St Louis, MA, USA), 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 1 mM AEBSF. For ErbB4 immunoprecipitations, 3 mg of tumor protein lysate or 6 mg of mammary gland protein lysate were incubated with 6 mg of mouse monoclonal ErbB-4 sc-8050 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) with 500 ml of TNEN buffer (Schroeder and Lee, 1998) , with Complete protease inhibitors (Roche), and Phosphatase Inhibitor Cocktail II (Sigma), 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 1 mM AEBSF for 1 h at 41C with tumbling. Slurry (50/50 of 50 ml) of ImmunoPure Immobilized Protein A (Pierce, Rockford, IL, USA) was added and incubated for 2.5 h at 41C with tumbling. The immune complexes were washed five times with 1 ml of TNEN plus inhibitors and eluted in 2 Â PSB (4% SDS, 125 mM Tris-HCl, pH6.8, 20% glycerol, 10 mM EDTA, 0.001% bromophenol blue, 0.2 M DTT, 10% b-mercaptoethanol added fresh). One-half of each eluate was resolved by electrophoresis on a NuPAGE Novex 4-15% Bis-Tris gel (Invitrogen, Carlsbad, CA, USA) and the proteins were transferred for 3 h at 40 mA to nitrocellulose membrane. The membrane was blocked in 5% milk in PBS-N (phosphatebuffered saline þ 0.05% NP-40) and probed with primary antibody rabbit polyclonal ErbB4 antibody (Santa Cruz, sc-283) at a 1:11 000 dilution and secondary antibody antirabbit-HRP at 1:10 000 dilution. Detection reagents used were SuperSignal West Pico Chemiluminescent Substrate or SuperSignal West Femto Maximum Sensitivity Substrate (Pierce).
Tumor analysis
Tumor volumes were based on digital caliper measurements, and were calculated as d 2 Â D Â p/6 where d represented the smaller diameter, and D the larger diameter. Histological analysis of tumors was based on a grading system used in analysis of human breast tumors. Evaluation of the tumors is based on cytologic criteria including mitotic count, nuclear pleomorphism, hyperchromasia, irregular nuclear membrane, presence of nucleoli, and necrosis. Twenty blinded samples (10 samples of recombined Neu-Cre-ErbB4 flox/null mice and 10 samples of recombined Neu-Cre-ErbB4 flox/WT mice) were evaluated. Several areas of each tumor were analysed microscopically and given scores of 1, 2 or 3 to describe the nuclear grades of the tumor cells.
Statistical analysis
To assess time until tumor development, Kaplan-Meier estimates were used to calculate the survival function. The log-rank test was applied to ascertain differences in the survival curves. To examine the absence or presence of lung metastases, the w 2 test was used.
